Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:1239 (28 May), doi:10.1136/bmj.38441.429618.8F (published 23 May 2005)
Oliver Rivero-Arias, research officer1, Helen Campbell, research officer1, Alastair Gray, professor of health economics1, Jeremy Fairbank, consultant orthopaedic surgeon2, Helen Frost, research fellow3, James Wilson-MacDonald, consultant orthopaedic surgeon2, for the Spine Stabilisation Trial Group
1 Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford OX3 7LF, 2 Nuffield Orthopaedic Centre, Oxford OX3 7LD, 3 Division of Health in the Community, University of Warwick, Warwick CV4 7AL
Correspondence to: H Campbell helen.campbell{at}dphpc.ox.ac.uk
Design Economic evaluation alongside a pragmatic randomised controlled trial.
Setting Secondary care.
Participants 349 patients randomised to surgery (n = 176) or to an intensive rehabilitation programme (n = 173) from 15 centres across the United Kingdom between June 1996 and February 2002.
Main outcome measures Costs related to back pain and incurred by the NHS and patients up to 24 months after randomisation. Return to paid employment and total hours worked. Patient utility as estimated by using the EuroQol EQ-5D questionnaire at several time points and used to calculate quality adjusted life years (QALYs). Cost effectiveness was expressed as an incremental cost per QALY.
Results At two years, 38 patients randomised to rehabilitation had received rehabilitation and surgery whereas just seven surgery patients received had both treatments. The mean total cost per patient was estimated to be £7830 (SD £5202) in the surgery group and £4526 (SD £4155) in the intensive rehabilitation arm, a significant difference of £3304 (95% confidence interval £2317 to £4291). Mean QALYs over the trial period were 1.004 (SD 0.405) in the surgery group and 0.936 (SD 0.431) in the intensive rehabilitation group, giving a non-significant difference of 0.068 (0.020 to 0.156). The incremental cost effectiveness ratio was estimated to be £48 588 per QALY gained (£279 883 to £372 406).
Conclusion Two year follow-up data show that surgical stabilisation of the spine may not be a cost effective use of scarce healthcare resources. However, sensitivity analyses show that this could changefor example, if the proportion of rehabilitation patients requiring subsequent surgery continues to increase.
For surgery patients, the local operating surgeon decided the type of spinal stabilisation used. Rehabilitation patients attended a paced exercise and education programme based on principles of cognitive behaviour therapy of about 75 hours' duration in total. We followed patients and collected back pain related NHS data and data on use of resources by patients to 24 months after randomisation. Patients who considered that their allocated treatment for chronic low back pain had failed could have further treatment including surgery. At baseline, six, 12, and 24 months, patients completed the EuroQol EQ-5D questionnaire, a generic health outcome instrument used to estimate utility scores3 and quality adjusted life years (QALYs).
Resource use
Patient specific data on the use of NHS resources included initial treatments, other back pain related hospital inpatient and outpatient visits, primary care contacts, and prescribed items of medication. We also collected data on over the counter medications purchased and visits made to private practitioners. Unless otherwise indicated, we used national average unit costs. All costs calculated are expressed in 2002-3 pounds sterling, inflated to this base year where appropriate.4
Spinal fusion surgery
A "micro" approach to the costing of surgery used patient specific data itemised by use of resources. We costed duration spent by each patient in the operating theatre to allow for the time of staff involved and use of the theatre.4
5 We used unit costs obtained from the lead investigating centre to value types and numbers of surgical implants and intraoperative spinal x rays.
We calculated costs for anaesthetic agents and blood products administered during each patient's surgery. Finally, we costed each patient's surgery related inpatient stay in hospital.6
Intensive rehabilitation
For each patient, we collected information on the number of half day rehabilitation sessions attended and applied staff costs per session.4 Patients had one hydrotherapy session per day, valued by using a unit cost from the lead investigating centre. We costed exercise equipment, and use of the hospital gym and a meeting room by adding 15% (the overhead rate employed by the lead investigating centre) to staff, hydrotherapy, and equipment costs. Finally, we costed overnight accommodation at either a private bed and breakfast (paid for by the NHS) or on a hospital ward.
Other back pain related NHS contacts
Patients reported attendances at hospital outpatient clinics for spinal surgery, physiotherapy, and other back pain related care at six, 12, and 24 months, which we then costed. We used the mean cost of the initial fusion procedures (calculated as described above) to cost hospital admissions for unplanned spinal fusion surgeries. Admissions for investigations included the cost of the evaluative procedure (provided by the lead investigating centre) plus overnight hotel costs on a general medical ward. We costed visits to and home visits from general practitioners and practice nurses.4 We used the average cost of a rehabilitation programme (calculated as described above) to cost any additional intensive rehabilitation.
Patients' costs
Patients reported contacts with private complementary practitioners, for which we obtained costs from relevant national organisations. Patients also documented items of medication prescribed, and the cost of over the counter medication purchased for back pain (see bmj.com for more details of costing methods).
Paid employment
Patients reported their employment status, occupation, and hours worked at baseline, six, 12, and 24 months. We calculated and costed total hours worked by each patient.7
Health related quality of life and quality adjusted life years
We used the EuroQol EQ-5D social tariff, estimated from a representative sample of the UK population, to convert patients' responses to the EuroQol EQ-5D questionnaire at baseline, six, 12, and 24 months into single utility levels.8 We then constructed patient specific utility profiles, assuming a straight line relation between each of the patient's utility levels. We calculated the number of QALYs experienced by each patient from baseline to 24 months as the area beneath this profile.
Discounting
We discounted costs and effects at an annual rate of 3.5%.
Statistical analysis
A small amount of trial data (12% of follow-up resource use items, 10% of utility scores, and 14% of work status data) were missing between baseline and 24 months. We used multiple imputation to replace missing values (see bmj.com).
We carried out incremental analysis, with the mean cost difference between surgery and rehabilitation divided by the mean QALY difference to give the incremental cost effectiveness ratio (ICER) and the non-parametric percentile method for calculating the confidence interval around this ratio. We used the cost effectiveness acceptability curve to show the probability that surgery is cost effective at two years for different values of the NHS's willingness to pay for an additional QALY.
|
Intensive rehabilitationTable 1 shows a breakdown of the mean total cost of intensive rehabilitation among the 151 patients who attended rehabilitation. The total cost was estimated to be £1615 (SD £644). Including zero rehabilitation programme costs for the 22 patients who did not attend, averaging across all 173 patients generated a cost estimate of £1410 (SD £808). Intensive rehabilitation was substantially less costly than surgery (cost difference £4601, 95% confidence interval £4013 to £5189, P < 0.001).
Other back pain related NHS costs
Forty eight patients randomised to rehabilitation underwent surgical stabilisation of the spine10 instead of rehabilitation, 38 in addition to rehabilitation. These unplanned surgery costs averaged £2128 per patient across the rehabilitation group (see bmj.com). This was greater than the corresponding cost of £451 in the surgery group, which was primarily attributable to 11 patients who required spinal re-operations.
Fourteen surgery patients underwent unplanned intensive rehabilitation (seven instead of surgery, seven as well as surgery). These costs amounted to £162 per patient. The overall mean cost per patient of follow-up back pain related NHS contacts was £1302 lower in the surgery group (95% confidence interval £1999 to £605, P < 0.001).
Patient costs
Patient costs related to back pain were similar in both arms (see bmj.com).
Overall costs
Table 2 shows costs at two years, with the cost difference favouring intensive rehabilitation.
|
Return to work
See bmj.com for comparisons of paid employment, hours worked and gross earnings between the surgery group and rehabilitation group; differences were all non-significant.
Utility
We found no significant differences in utility at any of the follow-up points (fig 1). A notable difference in utility existed at baseline (0.35 for surgery, 0.41 for rehabilitation). Adjusting for such a difference produced a mean QALY difference in favour of surgery of 0.068 (0.02 to 0.156, P = 0.13; mean 1.004 (SD 0.405) for surgery and 0.936 (SD 0.431) for rehabilitation).
|
|
Sensitivity analysis
We used sensitivity analysis to examine uncertainty surrounding the use of different surgical techniques for spinal stabilisation. Assuming any patient in the trial receiving surgery underwent posterolateral fusion, the least costly technique at £6170, the incremental cost per QALY would fall to £35 338 (£188 876 to £410 404). Alternatively had all patients undergone 360° fusion, the most costly technique at £9279, the incremental cost per QALY would rise to £60 765 (£420 210 to £617 081).
If the difference in utility observed at 24 months (0.566 for surgery and 0.532 for rehabilitation after adjustments for baseline) was maintained for a further two years, the incremental cost per QALY at four years would fall to £25 398 (£13 121 to £75 916).
|
We also examined the impact of patients receiving other treatments subsequent to their allocated therapy. At two years, 45 patients had received both treatments. Holding all else constant and assuming patients in each arm would continue to receive both treatments in years three, four, and five at the rates observed in years one and two, the cost difference is reduced to £1144 (£312 to £2600) and the cost per QALY to £16 824 (£156 358 to £138 911). If the trend continued but at half the rate observed in years one and two, the excess cost of the surgery arm at five years would fall to £2165 (£904 to £3425) and the cost per QALY to £31 838 (£407 056 to £283 783).
Strengths of the study
The main strength lies in the pragmatic approach adopted by the randomised controlled trial. Patients were not denied alternative healthcare interventions for chronic pain of the low back, so treatment patterns observed are likely to reflect those prevailing in routine practice.
At 24 months, the numbers of patients receiving both trial interventions differed significantly between the two arms. It is possible that this difference will increase beyond the two year follow-up point, and sensitivity analyses have shown that this could substantially affect the cost effectiveness of surgery.
Only one other economic evaluation has compared operative and conservative treatment,10 but rehabilitation included in that study focused primarily on routine physiotherapy.
Conclusion
Although a policy of spinal fusion surgery as first line therapy for chronic low back pain seems not to be a cost effective use of healthcare resources at two year follow-up, our analyses have shown that this conclusion could alter if the number of rehabilitation patients subsequently receiving surgery continues to increase in the future.
Additional details of the costing method, the participating units, and the members of the MRC steering committee are on bmj.com
This is the abridged version of an article that was posted on bmj.com on 23 May 2005: http://bmj.com/cgi/doi/10.1136/bmj.38441.429618.8F
We thank the patients who permitted a difficult decision to be made for them, physiotherapists and surgeons both inside and outside the trial who helped develop the protocol and made the study possible, Anthony Morton for provision of unit costs, the Medical Research Council for supporting the study, and the NHS R&D programme (especially Richard Lilford) for supporting and promoting the study.
Contributors: See bmj.com
Funding: This study was supported by the UK Medical Research Council. The NHS (326) or private patient insurance (23) funded the treatment of patients. The Health Economics Research Centre is partly funded by the National Coordinating Centre for Research Capacity Development. JF and JW-M receive funding from Synthes for a spinal fellow.
Competing interests: None declared.
Ethical approval: Granted by 15 local research ethics committees and one multicentre research ethics committee.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses